// App-Quantinova.ai

57 : Sequence decision making for cabazitaxel (Cbz) versus abiraterone (Abt) or enzalutamide (Enz) post-docetaxel (Dtx) in a publicly funded health care system.

Researchers

Presenter

  • Alexander Watson

Principal Investigators

  • Richard Gagnon

  • Eugene Batuyong

  • Nimira S. Alimohamed

  • Richard M. Lee-Ying

Medical Centers

  • University of Calgary, Calgary, AB, Canada

  • Tom Baker Cancer Center - University of Calgary, Calgary, AB, Canada

  • Tom Baker Cancer Center - University of Calgary, Calgary, AB, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Enzalutamide

  • Cabazitaxel

  • CB-7598

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved